Search for other papers by Martin Zweifel in
Google Scholar
PubMed
Search for other papers by Beat Thürlimann in
Google Scholar
PubMed
Search for other papers by Salome Riniker in
Google Scholar
PubMed
Search for other papers by Patrik Weder in
Google Scholar
PubMed
Search for other papers by Roger von Moos in
Google Scholar
PubMed
Search for other papers by Olivia Pagani in
Google Scholar
PubMed
Search for other papers by Martin Bigler in
Google Scholar
PubMed
Search for other papers by Karin M Rothgiesser in
Google Scholar
PubMed
Search for other papers by Christiane Pilop in
Google Scholar
PubMed
Search for other papers by Hanne Hawle in
Google Scholar
PubMed
Search for other papers by Peter Brauchli in
Google Scholar
PubMed
Search for other papers by Coya Tapia in
Google Scholar
PubMed
Search for other papers by Wolfgang Schoenfeld in
Google Scholar
PubMed
Search for other papers by Cristiana Sessa in
Google Scholar
PubMed
Search for other papers by for the Swiss Group for Clinical Cancer Research (SAKK) in
Google Scholar
PubMed
Introduction For the treatment of breast cancer (BC), testosterone was already used extensively between the 1930s and 1960s with anecdotal tumour responses (especially in bone metastases) seen in up to 20% of treated women ( 1 , 2 , 3 , 4
Search for other papers by Ahmet Uçar in
Google Scholar
PubMed
Search for other papers by Nurçin Saka in
Google Scholar
PubMed
Search for other papers by Firdevs Baş in
Google Scholar
PubMed
Search for other papers by Nihal Hatipoğlu in
Google Scholar
PubMed
Search for other papers by Rüveyde Bundak in
Google Scholar
PubMed
Search for other papers by Feyza Darendeliler in
Google Scholar
PubMed
blood samples for glucose and lipids (total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, and triglycerides (TGs)), serum insulin, LH, FSH, DHEAS, total testosterone, and high-sensitivity C
Search for other papers by T S Nilsen in
Google Scholar
PubMed
Search for other papers by L Thorsen in
Google Scholar
PubMed
Search for other papers by C Kirkegaard in
Google Scholar
PubMed
Search for other papers by I Ugelstad in
Google Scholar
PubMed
Search for other papers by S D Fosså in
Google Scholar
PubMed
Search for other papers by T Raastad in
Google Scholar
PubMed
E3 ligases promote ubiquitin conjugation of proteins destined for breakdown by the 26s proteasome ( 10 ). Removal of testosterone has been shown to increase the expression of muscle-specific E3 ligases ( 11 ), and this may also play a role in ADT
Search for other papers by Muriel Houang in
Google Scholar
PubMed
Search for other papers by Thao Nguyen-Khoa in
Google Scholar
PubMed
Département de Métabolomique Clinique, Hôpital Saint-Antoine, AP-HP Sorbonne Université, Paris, France
Search for other papers by Thibaut Eguether in
Google Scholar
PubMed
Département de Métabolomique Clinique, Hôpital Saint-Antoine, AP-HP Sorbonne Université, Paris, France
Search for other papers by Bettina Ribault in
Google Scholar
PubMed
Search for other papers by Séverine Brabant in
Google Scholar
PubMed
Université de Paris, INSERM, Institut IMAGINE, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
Search for other papers by Michel Polak in
Google Scholar
PubMed
Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France
Hôpital Armand Trousseau, AP-HP Sorbonne Université, Paris, France
Search for other papers by Irène Netchine in
Google Scholar
PubMed
Département de Métabolomique Clinique, Hôpital Saint-Antoine, AP-HP Sorbonne Université, Paris, France
Search for other papers by Antonin Lamazière in
Google Scholar
PubMed
, a mixture of the deuterated internal standard (IS) (150 µL containing 17-OHP-d8, testosterone-d4, D4-androstenedione (D4A)-d5, and 21-deoxycortisol (21-DF)-d8)) was added to 150 µL of serum. The solution was mixed and left standing for 5 min, and
Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA
Veterans Affairs Medical Center, Ann Arbor, Michigan, USA
Search for other papers by Richard J Auchus in
Google Scholar
PubMed
with the recommendations of professional societies, and the guidance of the United States Food and Drug Administration. The AACE position statement systematically reviews the patterns of misuse for testosterone, growth hormone (rhGH), thyroxine and
Department of Clinical Sciences and Community Health, Università degli Studi, Milan, Italy
Search for other papers by Elena Galazzi in
Google Scholar
PubMed
Search for other papers by Paolo Duminuco in
Google Scholar
PubMed
Search for other papers by Mirella Moro in
Google Scholar
PubMed
Search for other papers by Fabiana Guizzardi in
Google Scholar
PubMed
Search for other papers by Nicoletta Marazzi in
Google Scholar
PubMed
Division of Auxology and Metabolic Diseases, IRCSS Istituto Auxologico Italiano, Piancavallo (VB), Italy
Search for other papers by Alessandro Sartorio in
Google Scholar
PubMed
Search for other papers by Sabrina Avignone in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, Università degli Studi, Milan, Italy
Search for other papers by Marco Bonomi in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, Università degli Studi, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Search for other papers by Maria Teresa Bonati in
Google Scholar
PubMed
inhibin B and undetectable total testosterone (TTe) levels ( Table 1 ). He was normosmic at Brief-Smell Identification test (B-SIT) and normal central olfactory structures were confirmed using MRI. His karyotype was 46,XY. At the age of 15 years, he
Tropical Institute of Reproductive Medicine, Cuiabá, Mato Grosso, Brazil
Search for other papers by Sebastião Freitas de Medeiros in
Google Scholar
PubMed
Search for other papers by Márcia Marly Winck Yamamoto in
Google Scholar
PubMed
Search for other papers by Matheus Antônio Souto de Medeiros in
Google Scholar
PubMed
Search for other papers by Bruna Barcelo Barbosa in
Google Scholar
PubMed
Search for other papers by José Maria Soares Junior in
Google Scholar
PubMed
Search for other papers by Edmund Chada Baracat in
Google Scholar
PubMed
, 33 ). Biochemical hyperandrogenism was defined by at least one of the following criteria: total testosterone ≥2.1 nmol/L, free testosterone (FT)≥0.03 pmol/L, dehydroepiandrosterone sulfate (DHEAS) ≥6.7 µmol/L, androstenedione (A4) ≥8.6 nmol/L, and
Search for other papers by Zofia Kolesinska in
Google Scholar
PubMed
Search for other papers by James Acierno Jr in
Google Scholar
PubMed
Search for other papers by S Faisal Ahmed in
Google Scholar
PubMed
Search for other papers by Cheng Xu in
Google Scholar
PubMed
Search for other papers by Karina Kapczuk in
Google Scholar
PubMed
Search for other papers by Anna Skorczyk-Werner in
Google Scholar
PubMed
Search for other papers by Hanna Mikos in
Google Scholar
PubMed
Search for other papers by Aleksandra Rojek in
Google Scholar
PubMed
Search for other papers by Andreas Massouras in
Google Scholar
PubMed
Search for other papers by Maciej R Krawczynski in
Google Scholar
PubMed
Search for other papers by Nelly Pitteloud in
Google Scholar
PubMed
Search for other papers by Marek Niedziela in
Google Scholar
PubMed
testosterone were measured by radioimmunoassays: Active Androstenedione RIA (Beckman Coulter, Immunotech) and TESTO-RIA-CT (DIAsource ImmunoAssays S.A., Belgium), respectively. Anti-Müllerian hormone (AMH) and inhibin B were evaluated by ELx800 Absorbance
Search for other papers by Estelle Bonnet in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de psychopathologie du développement, Bron, France
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Centre de biologie et pathologie Est, Service d’hormonologie, d’endocrinologie moléculaire et des maladies rares, Bron, France
Search for other papers by Mathias Winter in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Centre de biologie et pathologie Est, Service d’hormonologie, d’endocrinologie moléculaire et des maladies rares, Bron, France
Search for other papers by Delphine Mallet in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service Endocrinologie Moléculaire et Maladies Rares, Bron, France
Search for other papers by Ingrid Plotton in
Google Scholar
PubMed
Search for other papers by Claire Bouvattier in
Google Scholar
PubMed
Search for other papers by Maryse Cartigny in
Google Scholar
PubMed
Search for other papers by Laetiti Martinerie in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
Search for other papers by Anne Bachelot in
Google Scholar
PubMed
Search for other papers by Frédéric Huet in
Google Scholar
PubMed
Search for other papers by Sabine Baron in
Google Scholar
PubMed
Search for other papers by Muriel Houang in
Google Scholar
PubMed
Search for other papers by Sylvie Soskin in
Google Scholar
PubMed
Search for other papers by Anne Lienhardt in
Google Scholar
PubMed
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
Search for other papers by Cyril Amouroux in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de chirurgie Uro-viscérale et de Transplantation de l’Enfant, Bron, France
Search for other papers by Aurore Bouty in
Google Scholar
PubMed
Search for other papers by Lise Duranteau in
Google Scholar
PubMed
Search for other papers by Rémi Besson in
Google Scholar
PubMed
Search for other papers by Alaa El Ghoneimi in
Google Scholar
PubMed
Search for other papers by Dinane Samara-Boustani in
Google Scholar
PubMed
Search for other papers by François Becmeur in
Google Scholar
PubMed
Search for other papers by Nicolas Kalfa in
Google Scholar
PubMed
Search for other papers by Françoise Paris in
Google Scholar
PubMed
Search for other papers by François Medjkane in
Google Scholar
PubMed
Hospices Civils de Lyon, Groupement Hospitalier Est, Service d’endocrinologie, Bron, France
Search for other papers by Aude Brac de la Perrière in
Google Scholar
PubMed
Centre National de Référence Maladies Rares du développement génital du fœtus à l’adulte DEV-GEN, Hospices Civils de Lyon, Bron, France
Search for other papers by Patricia Bretones in
Google Scholar
PubMed
Université Claude Bernard, Lyon, France
Search for other papers by Hervé Lejeune in
Google Scholar
PubMed
Centre National de Référence Maladies Rares du développement génital du fœtus à l’adulte DEV-GEN, Hospices Civils de Lyon, Bron, France
Université Claude Bernard, Lyon, France
Search for other papers by Marc Nicolino in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de chirurgie Uro-viscérale et de Transplantation de l’Enfant, Bron, France
Université Claude Bernard, Lyon, France
Search for other papers by Pierre Mouriquand in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de chirurgie Uro-viscérale et de Transplantation de l’Enfant, Bron, France
Search for other papers by Daniela-Brindusa Gorduza in
Google Scholar
PubMed
Centre National de Référence Maladies Rares du développement génital du fœtus à l’adulte DEV-GEN, Hospices Civils de Lyon, Bron, France
Search for other papers by Claire-Lise Gay in
Google Scholar
PubMed
determination of the testosterone/DHT ratio (elevated at baseline and/or after human chorionic gonadotrophin (hCG) stimulation test in SRD5A2 deficiency) and of the testosterone/androstenedione ratio (low at baseline and after hCG stimulation test in HSD17B3
Search for other papers by Shilpa Lingaiah in
Google Scholar
PubMed
Search for other papers by Laure Morin-Papunen in
Google Scholar
PubMed
Search for other papers by Terhi Piltonen in
Google Scholar
PubMed
Search for other papers by Inger Sundström-Poromaa in
Google Scholar
PubMed
Search for other papers by Elisabet Stener-Victorin in
Google Scholar
PubMed
Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Juha S Tapanainen in
Google Scholar
PubMed
/ASRM) consensus definition ( 25 ). Ovarian morphology was assessed by means of transvaginal ultrasonography in all subjects. Biochemical hyperandrogenism was defined as serum testosterone ≥2.3 nmol/L, according to the upper limits of the accredited laboratory at